Google
NVO Stock Analysis — NOVO NORDISK A/S (Healthcare >> Drug Manufacturers - General)
NVO FAQ
What is NVO's P/E ratio?
NOVO NORDISK A/S (NVO) currently trades at a P/E ratio of 1.87.
What is NVO's ROE?
NOVO NORDISK A/S reports a Return on Equity (ROE) of 60.06%.
What is NVO's dividend yield?
NOVO NORDISK A/S offers a dividend yield of 3.49%.
What is NVO's Quality Score?
Our AI rates NVO's overall financial quality at 54 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy NVO?
Our AI Timing Score for NVO is 89 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does NVO belong to?
NOVO NORDISK A/S is classified under the Healthcare >> Drug Manufacturers - General sector on the NYSE exchange
NVO AI Analysis Summary
Our AI summary for NVO: NOVO NORDISK A/S (NYSE), Healthcare >> Drug Manufacturers - General sector. The stock currently trades at a P/E of 1.87, ROE of 60.06%, a dividend yield of 3.49%. Its financial Quality Score stands at 54/100 — mid-range fundamentals relative to the market. The AI Timing Score is 89/100 — multiple technical signals currently support price momentum. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.
|
USD 47.08
Price
-4.53
(-8.78%)
Day Change
|
|
|---|
NVO, the overall quality is not quite good ( Quality = 54) but the timing to buy is ...(Sign In to See)...
Loading chart...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
Acceleration of ROE growth rate is below our criteria.
Negative growth of ROE in the last year.
ROA is too relatively low compare to ROE
Acceleration of ROA growth rate is below our criteria.
Growth of ROA was below our criteria in the last year.
Acceleration of net profit margin growth rate is below our criteria
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Momentum indicators aligned on the daily timeframe
In details, quality factors are ok , financial health is not quite good , and ability to make profit is good , ...
| Quality Factors |
|
69% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 1.96 From 30 days period |
| News Score | N/A |
| Magic Formula Rank by ROA |
59
GOOD
|
| Magic Formula Rank by ROE |
59
GOOD
|
| Magic Formula Rank by ROIC |
110
|
| Price | 47.08 |
| PBV / Sector |
1.12 / 2.68
GREAT
|
| Earning Per Share | 25.16 |
| PE / Sector |
1.87 / 27.65
GREAT
|
| PEG or PE/Growth / Sector |
0.07 / 0.28
GREAT
|
| Average 1M Daily Value |
445.54 M
GREAT
|
| Average 1W Daily Value |
589.29 M
|
| Timing Factors |
|
57% |
| Financial Health |
|
54% |
| Ability to Make Profit |
|
77% |
| Return to Investors |
|
62% |
| Registration Details |
| Analyze Date | 2026-08-01 08:00:15 |
| Symbol | NVO |
| Name | NOVO NORDISK A/S |
| Sector | Healthcare >> Drug Manufacturers - General |
| Market | NYSE |
| Listed Shares | 3,347.02 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 228,214.05 / 256,404.20 |
| News, Concensus, ... |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: Novo Alle 1, Bagsvaerd, Denmark, 2880
Phone: 45 44 44 88 88
Website: https://www.novonordisk.com
Employees: 67,900
Description: Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products. It operates through two segments, Obesity and Diabetes Care, and Rare Disease. The Obesity and Diabetes care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides NovoPen 6 and NovoPen Echo Plus, smart insulin pens; Dose Check, an insulin dose guidance application; growth hormone pens and injection needles; and Wegovy pill an oral glucagon-like peptide-1 (GLP-1) receptor agonist therapy for weight management. It operates in Europe, Canada, the United States, Japan, Korea, Oceania, Southeast Asia, Mainland China, Hong Kong and Taiwan, Latin America, the Middle East, and Africa. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Analyst Ratings & Target Price
ME vs SECTOR Healthcare >> Drug Manufacturers - General
Click a bubble to view stock details · Bubble size represents market capitalization share
